Broadcast Date: 
  • Time: 



In developing and manufacturing mRNA vaccines and therapeutics, selecting and using the appropriate quality or grade of mRNA raw materials can help you meet critical process, scale, quality, and regulatory needs. Process optimization and risk assessment will also help produce high-quality, high-yield mRNA consistently at scale while minimizing production time and cost.

In this GEN webinar, our guest speaker will address the key considerations for mRNA synthesis that help accelerate the development of mRNA vaccines and therapeutics. Moreover, we will learn about the importance of raw material selection for mRNA synthesis and discuss the scale-up of mRNA production for process development and commercialization. This information will feed into a comprehensive review of mRNA vaccine and therapeutic development workflows.


A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Thermo Fisher Scientific logo

Sirat Sikka
Sirat Sikka
Field Applications Scientist
Nucleic Acid Therapeutics
Thermo Fisher Scientific